Our portfolio

Descriptor

Developing and commercializing novel therapeutics derived from the innate human immune system to treat a range of infectious and inflammatory diseases. The lead product is currently in phase II clinical trials for acute kidney injury and ulcerative colitis.

Gene-based medicine targeting inherited metabolic disorders, ocular diseases and neurotherapy. The company’s lead product is currently in pivotal trials in patients with lipoprotein lipase deficiency type I.

Biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM)platform. Capable of generating and unparalleled diversity of potent antibodies against a broad range of deseases, the platform allows for more stringent lead selection criteria, thereby increasing the probability of success down the drug development road.

Argenta's clinical and preclinical pipeline of therapies for chronic respiratory diseases such as COPD, asthma and cystic fibrosis delivers both symptomatic relief (bronchodilators) and a disease modifying effect (anti-inflammatory). ADC4022, an anti-inflammatory for COPD, is currently undergoing a Phase IIa study. Argenta also generates income by providing contract research services.

Treatment of metastatic cancers and chronic infections using a proprietary platform technology, involving stimulating immune cells with messenger RNA. The lead programs are in treatment of metastatic renal cell carcinoma and HIV. Argos has a CD83 Soluble Protein for Transplant Rejection/Autoimmune Disorders in late preclinical development.

Bioceros B.V. is a privately-held company. It was founded in April 2003 as a biopharmaceutical R&D contract organization specialized in PER.C6 and CHO cell line generation for the biotechnological production of proteins, mainly monoclonal antibodies.

Focused on the use of herpes simplex virus as a biological treatment for cancer, Biovex is currently performing phase III trials for its lead product OncoVex.

Development of medical therapies for inflammatory cardiovascular diseases such as Abdominal Aortic Aneurysms, atherosclerosis and diabetes. The lead program for prevention of AAA growth and rupture is in phase II clinical development.

Focused on the treatment of advanced heart failure patients, CircuLite's microvad system's pump is designed to solve the problems of mechanical failure and blood clotting exhibited in artificial hearts and pumps.

Product-oriented biopharmaceutical company focused on the research and development of new and critical agents for immune modulation. The lead compound recombinant human interleukin-7 is a critical growth factor for T cells with unique features to rebuild the immune system and global enhancement of immune system functions

Gene transfer technology for effective ex vivo human delivery of proprietary genes to treat serious genetic and chronic disorders such as thalassemia and sickle cell anemia

Designs and develops percutaneous transcatheter devices for the treatment of mitral valve regurgitation (a significant factor in congestive heart failure.)

Innovative surgical device company developing BioDynamix™ Anastomosis technology. NiTi markets its ColonRing™ device - the next generation of closure technology for colorectal resection

PanGenetics is focused on the in-licensing and development of therapeutic antibodies. The lead program has been in a phase II study as chimeric antibody and its humanized counterpart will start clinical testing in 2009.

Develops innovative medical devices for the treatment of arterial diseases with an initial focus on peripheral artery disease (PAD).

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins®, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. IND filing for its lead Anticalin PRS-050, a next generation of anti-VEGF drug for the treatment of solid tumours, is expected for end 2009.

Promedior, Inc. is a clinical stage biopharmaceutical company developing novel therapeutics for the treatment of fibrotic and inflammatory diseases. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma; and acute and chronic nephropathy.

Developing treatments for oncology, based on proprietary third generation RNA chemistry, Locked Nucleic Acid. Santaris’ broad pipeline consists of multiple products in various stages of clinical and preclinical development in cancer, infectious disease and metabolic disorders.

Focused on the site specific treatment of lung diseases via the use of proprietary Sustained release Lipid Inhalation Targeting (SLITTM) technology. Transave’s lead product, SLIT-Amikacin, has received FDA and EMEA Orphan Drug designation and is in phase II trials in cystic fibrosis and bronchiectasis.

Developing a pipeline of ion channel drugs across a number of indications. Xention is currently undertaking a number of clinical projects in the neurological and cardiovascular disease areas.